Genetic Causes of Gestational Diabetes in the Emirati Population
试验速览
- 阶段
- 不适用
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- GDM Identification
研究概览
简要总结
The study aims to identify the number of MODY patients to be found among Emirati women with GDM as the incidence and prevalence of monogenic diabetes among this group of patients is unknown. This will enable improvements in diagnostics, treatment and the counselling of these women.
详细描述
The present study aims to perform systematic genetic screening of genes known as the cause of MODY in women diagnosed with gestational diabetes to estimate the prevalence of MODY. This is important to understand the extent to which monogenic diabetes is encountered for the first time during pregnancy. Once women with MODY developing GDM have been identified, biomarkers to identify these women can be found which will assist the clinical process of performing genetic screening in the right subset of patients. Also for the women participating in the present study, this is of great importance as correct genetic diagnosis will provide them with the needed information to receive optimal treatment, correct plan for follow-up and a more accurate prognosis in relation to risk of future complication and therefore prevention of such.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Currently pregnant women diagnosed with GDM.
- •Women with history of GDM (with negative GAD/IA2 antibodies if results available).
排除标准
- •Women with positive GAD/IA2 antibodies (if results available)
- •Women genetically diagnosed as MODY
结局指标
主要结局
GDM Identification
时间窗: through study completion, an average of 2 year
Identifying individuals with history of GDM or current diagnosis of GDM and analysing their GTT results and likelihood of MODY. GTT results will be extracted from patient's medical records.
次要结局
- Prevalence of MODY(through study completion, an average of 2 year)
- Next Generation Sequencing (NGS)(through study completion, an average of 2 year)
- Genetic test results validation(through study completion, an average of 2 year)
- Potential biomarkers(through study completion, an average of 2 year)
- Novel diabetes genes(through study completion, an average of 2 year)
- Clinical outcomes determination(through study completion, an average of 2 year)